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Fresolimumab treatment decreases biomarkers
and improves clinical symptoms in systemic
sclerosis patients
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BACKGROUND. TGF-β has potent profibrotic activity in vitro and has long been implicated in systemic sclerosis (SSc), as
expression of TGF-β–regulated genes is increased in the skin and lungs of patients with SSc. Therefore, inhibition of TGF-β
may benefit these patients.
METHODS. Patients with early, diffuse cutaneous SSc were enrolled in an open-label trial of fresolimumab, a high-affinity
neutralizing antibody that targets all 3 TGF-β isoforms. Seven patients received two 1 mg/kg doses of fresolimumab, and eight
patients received one 5 mg/kg dose of fresolimumab. Serial mid-forearm skin biopsies, performed before and after treatment,
were analyzed for expression of the TGF-β–regulated biomarker genes thrombospondin-1 (THBS1) and cartilage oligomeric
protein (COMP) and stained for myofibroblasts. Clinical skin disease was assessed using the modified Rodnan skin score (MRSS).
RESULTS. In patient skin, THBS1 expression rapidly declined after fresolimumab treatment in both groups (P = 0.0313
at 7 weeks and P = 0.0156 at 3 weeks), and skin expression of COMP exhibited a strong downward trend in both groups.
Clinical skin disease dramatically and rapidly decreased (P < 0.001 at all time points). Expression levels of other TGF-β–
regulated genes, including SERPINE1 and CTGF, declined (P = 0.049 and P = 0.012, respectively), and a 2-gene, longitudinal
pharmacodynamic biomarker of SSc skin disease decreased after fresolimumab treatment (P = 0.0067). Dermal myofibroblast
infiltration also declined in patient skin after fresolimumab (P < 0.05). Baseline levels of THBS1 were predictive of reduced
THBS1 expression and improved MRSS after fresolimumab treatment.
CONCLUSION. The rapid inhibition of TGF-β–regulated gene expression in response to fresolimumab strongly implicates
TGF-β in the pathogenesis of fibrosis in SSc. Parallel improvement in the MRSS indicates that fresolimumab rapidly reverses
markers of skin fibrosis.
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Table 1. Baseline demographic and clinical characteristics of
study patients (n = 15)
Characteristic

Value

Age, yr
Mean (SD)
Median
Sex F (M)
MRSS
Mean (SD)
Median
Presence of digital ulcers (no. [%])
FVC
Mean (SD)
Median
DLCO
Mean (SD)
Median
Presence of ILD on high-resolution chest CT (no. [%])
Disease duration
Mean (mo. from first non-Raynaud’s disease manifestation [SD])
Median (mo. from first non-Raynaud’s disease manifestation)
Raynaud’s disease manifestation
Mean (mo. before trial entry [SD])
Median (mo. before trial entry)
Diagnosis of SSc
Mean (mo. before trial entry [SD])
Median (mo. before trial entry)
Autoantibodies
Antinuclear antibody (no. [%])
Anti-Scl70 antibody (no. [%])
Anti-Pol3 (no. [%])
Anticentromere antibody (no. [%])
Antifibrillarin (no. [%])

51.73 (10.72)
51
11 (4)
26.9 (8.26)
24
9 (60)
94 (17.34)
90
82.13 (13.77)
82
1 (6.67)
19.21 (19.73)
15.5
37.86 (46.62)
19.5
8(6.23)
5
14 (93)
4 (27)
8 (53)
1 (7)
7 (47)

FVC, forced vital capacity; DLCO, diffusion capacity; ILD, interstitial lung
disease.

Introduction

Soon after its discovery as a transforming growth factor, TGF-β
was recognized to have potent profibrotic activity (1, 2). TGF-β promotes collagen synthesis, secretion, processing, and cross-linking
(3) as well as secretion of other matrix molecules, such as fibronectin and thrombospondin (4). All 3 TGF-β isotypes (TGF-β1, TGF-β2,
and TGF-β3) interact with the same receptor complex and have
wide-ranging, context-specific effects on cell proliferation and differentiation, embryological processes, and the immune system (5).
Fibrosis in patients with systemic sclerosis (SSc) affects the
skin in addition to internal organs: lungs, heart, and gastrointestinal tract (6). It represents a major unmet therapeutic challenge, as
treatment for SSc fibrotic disease is currently limited to cyclophosphamide, which has modest effects (7); immunoablation and stem
cell transplant offer a more dramatic benefit, which is associated
with significant treatment-associated morbidity and mortality (8).
Further, fibrosis is an end-stage process in many diseases, including many common diseases, such as liver cirrhosis complicating
viral or drug-induced hepatitis, renal fibrosis as the pathological
feature leading to many forms of end-stage renal disease, cardiac
2796
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fibrosis after myocardial infarctions and associated with hypertension, and pulmonary fibrosis, either idiopathic or associated
with a variety of other diseases or environmental exposures (9).
Although skin disease in SSc does not cause death, extensive skin
disease is associated with considerable morbidity and severity of
internal organ disease as well as disease-associated mortality (10).
In addition, skin fibrosis shares pathogenic features with fibrotic
disease at other sites in patients with SSc, suggesting that agents
successfully treating skin might show efficacy for other involved
organs (11). As skin can be easily biopsied, it provides a window
into understanding pathogenesis and also a methodology for
assessing response of a target organ.
Several factors have slowed development of therapeutics targeting fibrosis in SSc. The variable trajectory of disease progression
in different organs in patients with SSc has led to particular challenges in identifying efficacy in early-phase clinical trials; this has
included slow rates of progression of interstitial lung disease (12)
and spontaneous improvement of skin disease (13). In addition,
the relatively slow rate of change in skin disease, as assessed by the
main clinical outcome, the modified Rodnan skin score (MRSS),
and the relative insensitivity of the MRSS to change has led to the
notion that changes in the MRSS require long periods of observation to detect. The clinical heterogeneity of the disease and yearslong progression have made it difficult to demonstrate efficacy in
large, placebo-controlled, 12- to 24-month clinical trials in Ssc,
even in the early phase of clinical development (14), presenting a
significant obstacle for discovering effective therapies for SSc.
Biomarkers that correlate with the MRSS might act as surrogate outcome measures for the degree of skin disease in patients
with SSc and thus provide an approach for more quickly detecting
potential drug efficacy in early-phase SSc clinical trials. Biomarkers can be measured objectively and might be expected to change
more quickly than clinical outcome measures such as the MRSS.
We previously described a 4-gene, pharmacodynamic biomarker
of SSc skin disease, based on gene expression in a mid-forearm
skin biopsy (15). Two of the four genes making up the biomarker,
thrombospondin-1 (THBS1) and cartilage oligomeric protein
(COMP), are highly regulated by TGF-β. Thus, to test the importance of TGF-β in SSc skin fibrosis as well as to test a biomarkerbased approach to early-phase clinical trial design, we treated
patients with early, diffuse SSc with fresolimumab, a first-in-class
human IgG4 κ monoclonal antibody capable of neutralizing all
mammalian isoforms of TGF-β. The predefined primary efficacy
outcome for this trial was change in COMP and THBS1 mRNA
expression in skin after treatment compared with that at baseline.

Results

Patients. Patients were mostly female, with a median age of 51
years and median MRSS of 24 (Table 1). Only one patient showed
signs of interstitial lung disease, with a median forced vital
capacity of 90% predicted. Four patients (27%) had anti-Scl70
autoantibodies, and eight patients (53%) had anti–RNA polymerase (anti-Pol3) III autoantibodies. Anti-Pol3 autoantibodies
are typically seen in only about 11% of all patients with SSc (16)
but are much more common in patients with diffuse cutaneous
disease (17). Since anti-Pol3 autoantibodies are associated with
more severe skin disease and less severe interstitial lung disease
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Figure 1. CONSORT flow diagram. Schematic of patient
screening, enrollment, and
completion of the trial in the
two study groups.

(17), our entry criteria, which included only patients with diffuse
cutaneous disease and excluded patients with significant lung
disease, likely enriched for patients with this autoantibody specificity. Two groups of patients were treated with fresolimumab:
the first group (group 1, n = 7) was treated with 2 doses of 1 mg/
kg fresolimumab 4 weeks apart, and the second group (group 2,
n = 8) was treated with 1 dose of 5 mg/kg fresolimumab (Figure 1
and Figure 2A). Skin biopsies were performed at baseline (the day
of first infusion) and at 3 weeks (group 1) or 4 weeks (group 2),
7 weeks, and 24 weeks after the baseline biopsy (Figure 2A).
Skin biomarker gene expression of THBS1 shows a rapid decline
after fresolimumab treatment. The 2 groups of patients showed
dramatically different serum levels of fresolimumab, with group 2
reaching approximately 5 times higher serum levels 3 weeks after
treatment than group 1 (Figure 2B). Even after the first group of
patients received a second 1 mg/kg dose of study medication,
the relative levels of circulating fresolimumab were nearly twice
as high in the second group (receiving a single 5 mg/kg dose) at
7 weeks and subsequent time points due to the circulating half-life
of approximately 22 days.
Both treatment groups separately showed rapid declines in
THBS1 and COMP gene expression, the primary efficacy outcome measure (Figure 3, A–D, and Supplemental Table 1A; supplemental material available online with this article; doi:10.1172/
JCI77958DS1). Patients in the first dosing group showed a significant decline in median THBS1 expression (67.2% of baseline) at 7
weeks compared with that at baseline (P = 0.0313, Figure 3A and
Supplemental Figure 1A), and a trend toward decreased COMP
expression (77.1% of baseline) (P = 0.218, Figure 3C and Supplemental Figure 1C). Patients in the second dosing group showed
a more rapid decrease in THBS1 (70.0% of baseline; P = 0.0156,

Figure 3B and Supplemental Figure 1B) and COMP (66.7% of
baseline; P = 0.0781, Figure 3D and Supplemental Figure 1D),
which reached a nadir at week 3. Decreases in gene expression
seen at weeks 3 or 4 and week 7 were lost at week 24 (Figure 3,
A–D), a time when circulating fresolimumab was mostly metabolized (Figure 2B). However, in the first dosing group, the loss
of significant change at week 24 might reflect the fewer biopsies
available for analysis.
Changes in gene expression in study patients generally correlated with changes in MRSS (compare Supplemental Figure 1,
A and C with Supplemental Figure 1E and Supplemental Figure 1,
B and D with Supplemental Figure 1F). Examining the correlation
between the MRSS and biomarkers in all biopsies revealed a high
correlation for THBS1 (r = 0.63) and COMP (r = 0.62) (data not
shown), similar to correlations we reported previously between
the MRSS and gene expression (15). Baseline THBS1 and COMP
gene expression was strikingly higher in both SSc patient cohorts
than in healthy control skin, as we have reported previously (Figure 3, A–D, and ref. 15). Median baseline values were higher in the
first cohort (THBS1 = 11.63, COMP = 36.84) compared with those
in the second cohort (THBS1 = 5.97, COMP = 16.20; Figure 3, A–D),
as were median baseline MRSS values (25 and 22.5, respectively).
Summary statistics using all available data for patients entered
into both treatment groups showed that THBS1 and COMP expression declined rapidly after fresolimumab treatment (Table 2).
Gene expression results from skin biopsies following treatment in
the first group at 3 weeks and in the second group at 4 weeks were
combined for these analyses. Median THBS1 levels at week 3 or 4
were 77% of baseline, reaching a nadir at week 7 of 61% of baseline
THBS1 expression. Median COMP levels at week 3 or 4 and week
7 were 60% and 75% of baseline COMP expression , respectively.
jci.org   Volume 125   Number 7   July 2015
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Figure 2. Study design and pharmacokinetics of fresolimumab
in two dosing groups. (A) Trial protocol for each group shows
dosing levels and frequency and timing of skin biopsies. Red
arrows indicate skin biopsies. (B) Fresolimumab levels measured
in sera at 3, 7, 11, 17, and 24 weeks in group 1, which received 2
doses of 1 mg/kg at weeks 0 and 4 (blue diamonds), and group 2,
which received a single dose of 5 mg/kg fresolimumab at week 0
(red squares). Error bars indicate SD.

Examining gene expression of evaluable, paired biopsies from both
treatment groups, median THBS1 expression decreased by –1.5
(P = 0.0135) and –1 (P = 0.004) at week 3 or 4 and week 7, respectively (from baseline median of 8), and median COMP expression
decreased by –7.9 (P = 0.058) and –4.3 (P = 0.153) at week 3 or 4 and
week 7, respectively (from baseline median of 22.6).
To verify the results using an analytic method robust in
accounting for “missing-at-random” data, we used a repeatedmeasures model to take advantage of the multiple measurements per subject. Controlling for dose group, the predicted mean
changes from baseline (β coefficients) closely paralleled the results
obtained using all available data (Table 3). Changes in THBS1
and COMP expression were largest at week 7, with predicted
decreases of –3.4 (P = 0.018) and –3.6 (P = 0.135), respectively. The
dose by time interaction terms were significant for both THBS1
(P = 0.0012) and COMP (P = 0.0492), indicating that the patterns
of change over time differed by dose group.
To better understand the relationship between the skin score
at the biopsy site and gene expression, we compared gene expression of THBS1 and COMP to the local forearm skin score, the 0–3
score performed on the same day as the biopsy. The local skin
score correlated highly with the MRSS and also with expression of
both THBS1 and COMP (Supplemental Figure 2). We also examined autoantibody levels after treatment (week 11) compared with
those at baseline (Supplemental Figure 3). Anti-Scl70 autoantibody levels fell modestly in all patients (4 of 4), but our patient
group’s size was not sufficient to indicate a statistically meaningful result. Anti-Pol3 levels showed no consistent change, rising in
some patients and falling in others. We also examined the effects of
autoantibody status on the clinical response. The change in MRSS
in anti-Pol3–negative or anti-Scl70–negative patients (median
change = –12) was higher than that in anti-Scl70–positive (median
change = –5) or anti-Pol3–positive patients (median change = –2),
but these groups were too small to make a meaningful statistical
comparison. The change in MRSS was different when comparing
anti-Pol3–positive patients (median change in MRSS = –2) to antiPol3–negative patients (grouping anti-Scl70–positive patients with
patients negative for both anti-Scl70 and anti-Pol3; mean change
in MRSS = –6, P = 0.014) at week 7 but not at week 3 or 4 (P = 0.33).
2798
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Some studies have shown that longer disease duration is associated with spontaneous improvement in skin disease in patients
with SSc (18). However, in patients in this early disease cohort, we
found no relationship between the baseline disease duration and
the subsequent change in MRSS (Supplemental Figure 4).
Skin disease shows rapid improvement after fresolimumab
treatment. The primary clinical outcome in this trial, the MRSS,
declined rapidly in most patients, generally within several weeks
of the infusion (Table 2). Examining the change in MRSS in each
study group separately showed similar seeming response kinetics,
with both groups showing rapid decreases in mean MRSS as soon
as the first follow-up study visit, and then increasing skin scores by
the week 24 study visit, apparently representing recurrent disease
(Figure 3, E and F, and Supplemental Table 1B).
The median change in MRSS, using all available data across
both dose groups, was most striking at weeks 11 and 17, –6
(P = 0.0005) and –9.5 (P = 0.0024), respectively (Table 2). Many
patients then showed recurrent disease, i.e., an increase in the
MRSS at a later point in the trial. The repeated-measures model
reinforced the analysis of all available data (Table 3), with a nadir
in the predicted change of –8 at week 11 (P = 0.0002). There was
no statistically significant dose by time interaction in the repeatedmeasures model, indicating that the patterns of change over time
in MRSS were somewhat similar for the 2 dose groups (P = 0.4168).
Decreased expression of a coregulated cluster of TGF-β–regulated genes and macrophage-associated genes after fresolimumab
treatment. To further understand the genes regulated by fresolimumab in the study patients, biopsies were analyzed by microarray. Clustering of these genes revealed a readily recognizable
cluster of TGF-β–regulated genes that included both of the genes
predefined as the primary outcome measures: THBS1 and COMP
(Figure 4). All of the genes in this cluster were found to correlate
highly with the MRSS (Figure 4). Genes clustering with the primary outcome measures included several genes regulated by
TGF-β: connective tissue growth factor (CTGF, also known as
CCN2) (19), cadherin 11 (CAD11) (20), NADPH oxidase 4 (NOX4)
(21), collagen X α 1 (COL10A1) (22), and collagen XI, α 1 (23). We
quantified expression of several TGF-β and collagen genes by
RT-PCR. CTGF, SERPINE1, and COL10A1 expression levels all
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Figure 3. Changes in biomarker gene
expression and MRSS by study group.
(A and B) THBS1 and (C and D) COMP
gene expression and (E and F) MRSS from
study patients in (A, C, and E) group 1
(n = 7), which received 2 doses of 1 mg/kg
fresolimumab, and (B, D, and F) group 2
(n = 8), which received 1 dose of 5 mg/kg
fresolimumab. Dot plots show median
(horizontal bars) and statistical significance of THBS1 and COMP gene expression (Wilcoxon signed-rank test, using
available data). Box plots show median
(horizontal line), interquartile (box),
and 95% confidence limits (whiskers) of
MRSS. Line graphs showing changes in
individual patients over time are shown
in Supplemental Figure 1.

declined after fresolimumab treatment compared with those at
baseline (Figure 5, A–C).
We also examined the microarray expression of inflammatory
genes after fresolimumab treatment. CD14, CD163, and MS4A4A,
all genes expressed mainly in monocytes/macrophages, clustered
together (data not shown). Expression of CD163, tested by NanoString, trended lower after fresolimumab treatment (Figure 5D).
Decreased expression of a SSc skin pharmacodynamic biomarker
after fresolimumab treatment. We tested the effect of treatment
with fresolimumab on a recently developed, multianalyte, longitudinal pharmacodynamic biomarker (2GSSc skin biomarker; ref.
24). This biomarker is composed of weighted values for THBS1
and MS4A4A mRNA expression assessed by NanoString. The
2GSSc skin biomarker showed reduced expression at both week
3 or 4 and week 7 after fresolimumab treatment compared with
baseline expression levels (Figure 6A). We compared the 2GSSc
biomarker in samples from a clinical trial of nilotinib in SSc. This

trial included very similar patients with early, diffuse SSc (Supplemental Table 2), but skin biopsies were analyzed at baseline,
6 months, and 12 months. This longer time interval between biopsies would be expected to show more dramatic changes in the
2GSSc skin biomarker than seen in samples from fresolimumabtreated patients, due to the natural history of the disease. In contrast
to samples from fresolimumab-treated patients, nilotinib-treated
patients showed no significant change in 2GSSc skin biomarker at
6 and 12 months compared with that at baseline (Figure 6B).
Inhibition of myofibroblasts and plasminogen activator protein-1
in fresolimumab-treated patients. TGF-β stimulates fibroblast differentiation into myofibroblasts, the cell type consistently implicated in fibrosis in many diseases (25). Myofibroblasts are sensitive markers of SSc skin disease, and the intensity of myofibroblast
infiltration correlates highly with the severity of skin disease, as
assessed by the MRSS (26). In several patients, fresolimumab
treatment was associated with a particularly rapid, dramatic
jci.org   Volume 125   Number 7   July 2015
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to each other (r = –0.7 for both, Figure
8A). THBS1 also clustered with these
A
genes, correlating almost as highly as
CI (95%)
P value
ADAM12 and FN (r = –0.67). Patients
6.8–13.8
stratified dichotomously on the basis
5.1–11.7
of having higher than median base4.8–8.4
4.0–9.6
line ADAM12 expression were found
–4.9–0.9
0.01353
to significantly and more frequently
–5.7 – –0.7
0.004
respond to fresolimumab (decreased
–4.6–2.4
0.5566
THBS1 expression compared with
18.5–37.1
baseline; Figure 8B, P < 0.05).
11.9–31.5
We also examined whether
13.9–31.5
expression of genes might predict the
11.7–25.5
observed change in the MRSS. Baseline
–14.4–1.0
0.058
THBS1 expression robustly correlated
–7.9–0.9
0.1531
with the change in MRSS at week 3 or
–10.0–4.2
0.4316
4 and week 7 compared with that at
22.5–31.2
baseline (r = –0.38). Patients stratified
16.5–25.4
dichotomously on the basis of hav15.8–25.4
ing a higher median baseline THBS1
14.0–24.2
expression were found to respond
12.0–24.6
14.5–28.7
more frequently to fresolimumab,
–7.6 – –3.6
0.0002
both biochemically (decreased THBS1
–9.7 – –3.0
0.0032
expression compared with baseline,
–11.1 – –4.7
0.0005
P < 0.05, data not shown) and clini–11.5 – –4.7
0.0024
cally (decreased MRSS compared with
–8.9 – –0.7
0.0508
baseline, P < 0.05, Figure 8C).
Safety outcomes. The most significant adverse events were several
bleeding episodes and the common
occurrence of anemia (Table 4). Two
patients developed clinically significant gastrointestinal bleeding from gastric antral vascular ectasia (GAVE); one patient
(GC08) with a history of GAVE required hospitalization, and
both required transfusion. Both lesions were treated effectively
with argon laser photocoagulation. Gingival bleeding and/or
epistaxis were described by 3 patients, and 2 patients showed
subconjunctival hemorrhages. Hemoglobin levels decreased

Table 2. Summary statistics on all available data (dosing groups combined)
THBS1

Change

COMP

Change

MRSS

Change

Baseline
Week 3
Week 7
Week 24
Week 3
Week 7
Week 24
Baseline
Week 3
Week 7
Week 24
Week 3
Week 7
Week 24
Baseline
Week 3
Week 7
Week 11
Week 17
Week 24
Week 3
Week 7
Week 11
Week 17
Week 24

n

Mean

Median

SD

15
14
14
10
14
14
10
15
14
14
10
14
14
10
15
14
14
14
12
12
14
14
14
12
12

10.3
8.4
6.6
6.8
–2
–3.2
–1.1
27.8
21.7
22.7
18.6
–6.7
–3.5
–2.9
26.9
21
20.6
19.1
18.3
21.6
–5.6
–6.4
–7.9
–8.1
–4.8

8
6.2
4.9
5
–1.5
–1
–2.7
22.6
13.5
16.9
14.2
–7.9
–4.3
–5.3
24
19
18.5
16.5
13.5
17.5
–6
–5
–6
–9.5
–5

6.9
6.3
3.5
4.5
5.6
4.8
5.7
18.4
18.7
16.8
11.2
14.8
8.5
11.5
8.6
8.5
9.2
9.8
11.2
12.6
3.8
6.4
6.1
6
7.2

Wilcoxon signed-rank test on change from baseline.

A

decline in myofibroblast infiltration of the deep dermis (Figure 7,
A–C). All study patients showed a decrease in myofibroblast infiltration at week 3 or 4 after treatment with fresolimumab (Figure
7D, P = 0.022). The degree of myofibroblast infiltration changed
more consistently in patients receiving the higher dose of fresolimumab (second treatment group; data not shown).
Sections were also stained for the SERPINE1 gene product,
plasminogen activator protein-1 (PAI-1). PAI-1 has long been recognized as a target of TGF-β (27). We show above that SERPINE1
mRNA is highly upregulated in SSc skin and its levels are reduced
after fresolimumab treatment. PAI-1 protein staining was also
reduced in SSc skin (Supplemental Figure 5A). Additionally, we
examined dermal thickness in sections from patients after staining with trichrome. However, skin thickness was not found to
change after fresolimumab treatment. (Supplemental Figure 5B).
Baseline expression of TGF-β–regulated genes predicts response to
fresolimumab. In order to understand whether expression of some
genes might predict patient response to fresolimumab, we examined the relationship between microarray gene expression at baseline to the change in expression of THBS1 at week 3 or 4 and week
7 compared with baseline. A negative correlation would indicate
genes whose level of expression at baseline predicts a decrease in
THBS1 expression after fresolimumab treatment.
Clustering only genes showing correlations r < –0.6 revealed
two known TGF-β–regulated genes, ADAM metallopeptidase
domain 12 (ADAM12) and fibronectin (FN), clustering adjacent
2800
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Table 3. Repeated-measures model results
THBS1

COMP

MRSS

WeekA

β

Se (β)

P value

3/4
7
24
3/4
7
24
3/4
7
11
17
24

–1.8
–3.4
–1.5
–6
–3.6
–3.1
–5.1
–6.3
–8
–7.5
–3.2

1.5
1.3
2.1
3.9
2.3
3.4
1.1
1.6
1.6
1.7
2.2

0.2459
0.0184
0.4941
0.1503
0.1353
0.3832
0.0004
0.002
0.0002
0.0006
0.1744

A
Compared with Baseline, controlling for dosing group. β, β coefficients; Se
(β), standard error of β.
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Figure 4. Hierarchical clustering of skin gene expression in study patients. The gene cluster, including both primary outcome measures, THBS1 and
COMP, is shown. Samples from each study patient (n = 15) are shown as columns of gene expression (red, high gene expression; green, low gene expression; black, intermediate gene expression), labeled by study visit, starting with the baseline biopsy, followed sequentially by subsequent biopsies (top of
figure), with a blank column between each patient. Gene names and the correlation between each gene and the MRSS are shown to the right and far right,
respectively. GalNAc-T1, UDP-N-acetyl-α-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 1.

by more than 10% at some point in the trial in 10 of 15 (66.7%)
patients (Table 4 and Supplemental Figure 6), in most cases
resolving without further treatment. Most anemic patients had
iron studies consistent with anemia of chronic disease, although
several also appeared iron deficient.
One patient (GC13) with severe skin disease, who experienced rapid improvement in skin sclerosis (MRSS = 37 at baseline,
improving to 30 at 3 weeks) after receiving one dose of fresolimumab (5 mg/kg), subsequently developed recurrent skin disease (MRSS = 35 at week 11) and developed shortness of breath 12
weeks after fresolimumab dosing. This patient was subsequently
diagnosed with severe congestive heart failure and died of heart
failure 10 days later. A premorbid cardiac biopsy of this patient
showed severe cardiac fibrosis, a known complication of SSc (28).
In another patient, one premalignant lesion was identified, a
low-grade squamous intraepithelial cervical lesion found on routine PAP smear 17 weeks after fresolimumab dosing; subsequent
colposcopy showed mild dysplasia. This patient had a history of
abnormal PAP smears, a low-grade squamous intraepithelial
lesion, and a positive test for HPV DNA. Subsequent to the abnormal study PAP smear, the patient has had 2 normal PAP smears.

Discussion

Based on extensive in vitro and animal data, TGF-β has long been
suspected as an important mediator of fibrosis in SSc as well as
a variety of other fibrotic diseases, including renal, pulmonary,
cardiac, and liver fibrosis (29–31). However, to our knowledge
there has never previously been clinical data directly supporting its role in humans. Our data show that fresolimumab leads
to a rapid decrease of TGF-β–regulated biomarker genes. For the
predetermined primary efficacy outcome measures for the trial,
THBS1 expression in SSc skin declined significantly in both fresolimumab-treated groups, while COMP trended strongly toward
decreased expression in both groups. In addition microarray analyses showed that downregulation of these genes was associated
with downregulated expression of a larger cluster of known TGF-β–

regulated genes, including NOX4 and CTGF, both implicated as
secondary mediators of TGF-β signaling (21, 32). Several collagen
genes were also included in this cluster, consistent with a role for
fresolimumab on genes directly mediating fibrosis. Expression of
all of the genes in this cluster, most with r values greater than 0.4,
was found to correlate with the MRSS, suggesting that these genes
are part of a cluster of TGF-β–regulated genes that appear to play a
driving role in TGF-β–mediated skin fibrosis in SSc.
Further supporting the pivotal role of TGF-β in SSc pathogenesis, patients treated with fresolimumab showed a rapid, significant decrease in MRSS, which correlated closely with the degree
and speed of decline in the skin biomarkers. Thus, the biomarker
data strongly reinforce the clinical data, while robustly supplementing it as an objective measure. The rate of decline of the skin
score in these patients is unprecedented in clinical trials of even
much longer duration (18). The natural history of patients with
early, diffuse SSc, extracting from 7 large, placebo-controlled,
negative large trials (n = 429), showed median MRSS improvements (decreases in MRSS) of 2.9 and 3.4 at 6 and 12 months (13).
Thus, much larger and more rapid decreases in MRSS were seen
in fresolimumab-treated patients (decreases of 5.1, 6.3, and 8 at
week 3 or 4, 7, and 11, respectively).
TGF-β is also known to induce myofibroblasts (25), and the
intensity of myofibroblast staining correlates highly with the
degree of skin disease (26). Thus, decreased staining of myofibroblasts after fresolimumab treatment further supports the role
of TGF-β in SSc pathogenesis as well as the observed clinical effect
on skin disease. Expression of genes known to be highly regulated
by TGF-β, CTGF and SERPINE (which encodes PAI-1), was also
lower in patient skin samples 3 or 4 weeks after fresolimumab
treatment, strongly supporting the role of TGF-β in pathogenesis
and expression of these genes. On the other hand, skin thickness
did not change significantly after fresolimumab treatment. The
MRSS is primarily designed to detect changes in skin thickness;
however, the effect of fresolimumab on the MRSS is likely due
to changes in skin tightness and tethering that result from blockjci.org   Volume 125   Number 7   July 2015
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Figure 5. Changes in gene expression before and
after fresolimumab treatment. Skin biopsy RNAs
were analyzed for expression of TGF-β–regulated
genes, (A) CTGF, (B) SERPINE1, (C) and COL10A1, and
a macrophage marker, (D) CD163, at baseline and
after fresolimumab treatment. Levels from 5 healthy
controls skin samples are also shown. CTGF, SERPINE1, and COL10A1 mRNA expression was assayed by
RT-PCR; CD163 expression was assayed by NanoString.
Statistical significance was assessed by Wilcoxon
signed-rank. Error bars indicate SEM.

ing TGF-β. These clinical manifestations of skin tightness and
tethering might be due more to the presence of myofibroblasts
in SSc skin and to loss of subcutaneous fat, respectively, than to
increased skin thickness. Our data show that at least one of these
features, myofibroblast number, changes more rapidly than skin
thickness after TGF-β inhibition.
Notably, the statistically significant improvements in both
clinical score and biomarker expression observed early after fresolimumab treatment were lost by the last study visit (week 24),
7 or 8 drug half-lives after the last dose given in the first and second patient groups, respectively. Thus, these data further support
the role of fresolimumab in the observed declines in MRSS and
biomarker gene expression and indicate a need for longer treatment in future studies. Collectively, these observations strongly
support a key role for TGF-β in SSc pathogenesis.
Patients treated with fresolimumab showed a trend of
decreased levels of the macrophage/monocyte-associated genes,
CD163 and MS4A4A. The latter of these genes is the second of

Figure 6. Decreased 2GSSc biomarker level
in skin after fresolimumab treatment. Skin
RNAs from patients entered into (A) the fresolimumab trial or (B) a clinical trial of nilotinib
were assayed by NanoString for 2GSSc skin
biomarker levels in baseline, week 3 or 4, and
week 7 (fresolimumab) or at baseline and 6
and 12 months (nilotinib). Statistical significance was assessed by Wilcoxon signed-rank.
Error bars indicate SEM.
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two genes in the 2GSSc skin biomarker (24). The change in macrophage marker genes was less dramatic (and not statistically significant in this small trial) but might suggest that TGF-β also contributes to the perivascular inflammation seen in this disease. Indeed,
TGF-β is known to induce monocyte chemotaxis, in addition to
its antiinflammatory properties (33), and induces Th2, Th17, and
plasmacytoid dendritic cell migration into the skin of mice with
mutations found in patients with stiff skin syndrome that mimic
dermal fibrosis of SSc (34).
We found that baseline expression of THBS1 and ADAM12
was a predictive biomarker for improved THBS1 expression after
fresolimumab treatment and baseline THBS1 expression was predictive of improvement in the MRSS after fresolimumab treatment. These observations suggest that patients might be stratified for their likely response to TGF-β inhibition on the basis of
their pretreatment gene expression. Both THBS1 and ADAM12
are known to be induced by TGF-β (35, 36). THBS1 can also activate TGF-β, while ADAM12 has also been shown to contribute to
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Figure 7. Myofibroblast infiltration in
fresolimumab-treated patients. Sequential biopsies from patient GC17 are shown,
comparing (B) week 4 and (C) week 7 to (A)
baseline myofibroblast infiltration (original magnification, ×10). Arrows indicate
myofibroblasts. Insets show myofibroblast
staining in the deep dermis (original magnification, ×40). (D) Skin biopsies stained
for smooth muscle actin (SMA) were
scored by an observer blinded to biopsy
sample for intensity of myofibroblast infiltration. Median values for each time point
are shown by the red line with rectangular
symbols (*P < 0.01, comparing week 4 to
baseline, Wilcoxon ranked-sum).

TGF-β signaling through an interaction with the type II TGF-β
receptor (37). Notably, in recent studies, ADAM12+ pericytes were
shown to be progenitors of myofibroblasts induced after skin or
muscle injury, and deletion of ADAM12+ cells blocked fibrosis
(38). Thus, it is intriguing to consider a possible role for TGF-β
in stimulating ADAM12+ pericytes in the generation of myofibro
blasts and fibrosis in SSc skin.
An earlier study of the TGF-β mAb CAT-192 in SSc failed to
show any difference in change in MRSS between treatment groups
(39). Importantly, CAT-192 targets only TGF-β1 (40), with a dissociation constant of 150 nM, whereas fresolimumab is a much
higher-affinity antibody for TGF-β1 but also targets TGF-β2 and
TGF-β3, with dissociation constants of 2.3 nM, 2.8 nM, and 1.4 nM,
respectively (Genzyme, unpublished Biacore analyses). Thus, the
neutralizing activity against TGF-β2 and TGF-β3 or much higher
target affinity may be critical in the activity of fresolimumab in SSc.
The anti–TGF-β antibody fresolimumab (also known as
GC1008) has been tried previously in patients for several diseases.
In patients with focal segmental glomerulosclerosis (FSGS), fresolimumab treatment was associated with a decline in proteinuria
in some patients, suggesting possible efficacy in this disease, for
which TGF-β is also strongly implicated in pathogenesis (41, 42).
Like in SSc, THBS1 is overexpressed in FSGS renal glomeruli (43,
44), suggesting that it may provide a strong biomarker in other
TGF-β–mediated diseases.
Patients with malignant mesothelioma (n = 13) were treated
with 3 mg/kg fresolimumab for up to 6 doses, showing little clinical effect but also few adverse effects. One patient developed erythematous, verrucous papules on biopsy, showing atypical keratinocyte proliferation (45). In patients with malignant melanoma
(n = 28) or renal cell carcinoma (n = 1), patients received up to 4
doses of 15 mg/kg fresolimumab over a period of 56 days, with 5
patients also receiving an additional 4 doses ranging from 0.1 to
1 mg/kg (46). Minor bleeding (epistaxis and gingival bleeding)
was seen frequently in these patients. In addition, several patients
developed epithelial lesions suggestive of squamous cell carcinoma, rather than keratoacanthoma, which is more commonly

seen in patients receiving higher doses of medication. All but one
of these patients was ultimately diagnosed pathologically as having keratoacanthomas, and the lesions resolved spontaneously
after fresolimumab treatment was complete, a clinical course
more consistent with keratoacanthoma.
We did not see keratoacanthomas in our study; however, several patients had epistaxis, gum bleeding, or subconjunctival eye
hemorrhage, as reported in other studies of fresolimumab (46, 47).
Although the incidence of GAVE in this study group was similar to
that expected in such a patient cohort, the timing and severity of
these and other bleeding incidences in our study patients dictates
careful observation of this complication in future trials. Anemia
in the study patients has not been reported in past trials and may
be related to bleeding, SSc, and/or its treatment. Iron studies did
not clearly distinguish iron deficiency from anemia of chronic
disease (or both) in most patients. No patients showed evidence
of hemolysis, and most showed an inappropriate response to the
anemia (low or normal reticulocyte counts). Most patients were
also on proton pump inhibitors, known to block iron absorption,
and severe anemia associated with GAVE, though not correcting
with oral iron, responded promptly to intravenous iron, consistent
with underlying iron deficiency and preexisting gastrointestinal
blood loss. Thus, future studies of fresolimumab in patients with
SSc should include careful baseline evaluation for indolent gastrointestinal bleeding and iron deficiency.
Despite recent studies clarifying the natural history of diffuse
cutaneous SSc as a disease that frequently remits spontaneously,
the disease often progresses relentlessly and is associated with
considerable mortality through a variety of complications (48).
Although patients do not typically die directly of skin disease,
the underlying pathogenesis for fibrotic complications, including
fatal complications of the lung and bowel, is likely similar. Thus,
these complications may also be driven by TGF-β and potentially
amenable to inhibition by fresolimumab. Fresolimumab has been
well tolerated in several trials (described above) at higher doses
than those used in this study and multiple doses. The concern for
side effects from TGF-β inhibition needs to be carefully weighed
jci.org   Volume 125   Number 7   July 2015
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Figure 8. THBS1 and ADAM12 expression predicts response to fresolimumab. (A) 58 genes showing correlations with the change in THBS1 expression
at week 3 or 4 and week 7 compared with baseline of less than –0.6 were clustered. Baseline ADAM12, THBS1, and FN cluster together, showing strongly
negative correlations with the change in THBS1 expression after fresolimumab treatment at week 3 or 4 and week 7 (red, higher expression; green, lower
expression). Pearson correlations are shown to the right. (B) Patients were stratified into high (n = 14) and low (n = 14) baseline ADAM12 expression groups,
based on whether they exhibited greater or less than the median level of ADAM12 expression on microarray. Patients were then graphed according to
week 3 or 4 and week 7 THBS1 expression, compared with baseline (change in THBS1). Patient samples showing high baseline ADAM12 expression showed
greater decreases in THBS1 after fresolimumab than patient samples with low baseline ADAM12 expression (P < 0.05, Fisher’s exact test). (C) Patient samples were stratified into high (n = 14) and low (n = 14) baseline THBS1 expression groups, based on whether they exhibited greater or less than median level
of THBS1 expression on microarray. Samples were then graphed according to week 3 or 4 and week 7 THBS1 expression, compared with baseline (change in
THBS1). Samples showing high baseline THBS1 expression showed greater decreases in MRSS after fresolimumab than samples with low baseline THBS1
expression (P < 0.05, Fisher’s exact test).

against the prognosis of SSc and currently available therapeutics.
Cyclophosphamide and immunoablation with stem cell transplant
are both associated with neoplastic complications, and stem cell
transplant is associated with considerable transplant-associated
mortality (8). Fresolimumab is potentially a safer alternative.
These complications, as well as the wide array of other diseases
associated with organ fibrosis, may also be driven by TGF-β and
respond to fresolimumab. Thus, fresolimumab holds promise as a
potent antifibrotic therapeutic, which needs further study for the
safety of longer-term use and for treatment of skin, lung, and gastrointestinal tract fibrosis.

Methods

Patients. This single-center study was approved by the Boston University
Medical Campus Institutional Review Board and registered with clinicaltrials.gov identifier NCT01284322 prior to patient recruitment. The
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study was conducted after FDA review under Investigational New Drug
110704. A Data and Safety Monitoring Board, composed of two physicians external to the study investigators, reviewed all adverse events.
Patients ≥18 years of age were included who had SSc (49) with diffuse
cutaneous disease (50), a MRSS ≥15, and early disease, as defined by
occurrence of the first non-Raynaud’s disease symptom within 2 years
study entry. Patients with substantial pulmonary compromise (forced
vital capacity less than 80% predicted, diffusion capacity less than
70% predicted, or >20% fibrosis on computerized chest tomography);
recent (within 6 months of study entry) scleroderma renal crisis or elevated creatinine >2.0; significant arrhythmia, unstable angina, or clinical heart failure; elevated liver function tests >2.5 times normal; bowel
obstruction requiring hospitalization within 3 months or malabsorption
requiring parenteral nutrition; recent bleeding, anemia (Hgb <8.5), or
thrombocytopenia (platelet count <100,000/mm3); active infection;
or any history of malignancy or history of premalignancy within 5 years
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24, with skin biopsies performed again at week
7 and, optionally, if the patient was willing,
at week 24 at sites approximately 5 mm from
Adverse event
Combined n (%)
No. of subjects (wk from baseline visit
to first occurrence of adverse event)
but immediately adjacent to the most recent
biopsy. The MRSS was assessed at each study
Group 1, n = 7
Group 2, n = 8
visit by the same study physician. The scleroAnemiaA
10 (66.7)
5 (3, 7, 7, 7, and 17)
5 (3, 7, 7, 7, and 24)
derma-modified health assessment question1 (6.7)
1 (7)
ReticulocytosisB
6 (26.7)
1
5
ACDC
naire was administered at weeks 0, 7, and 24.
Heme-positive stool
2 (13.3)
1 (7)
1 (7)
Safety assessments. Safety was assessed at
2 (6.7)
1 (7)
1 (8)
Gastrointestinal bleedingD
each study visit using Common Terminology
2 (13.3)
1 (7)
1 (3)
EpistaxisE
Criteria for Adverse Events v4.0. Based on
2 (13.3)
1 (3)
1 (7)
Gingival bleedF
FDA protocol recommendations, all adverse
Bloodshot eye
1 (6.7)
1 (3)
events were considered related to the study
2 (13.3)
2 (10,17)
Subconjunctival eye hemorrhageG
drug unless there was a clear and identifiable
Face swelling
1 (6.7)
1 (0)
reason or explanation to reject casual relation.
Abnormal PAP smear
1 (6.7)
1 (17)
Due to concerns regarding possible promo1 (6.7)
1 (3)
Polyarthralgia/tendonitisD
tion of tumor progression by blocking TGF-β,
Emesis
1 (6.7)
1 (7)
in addition to routine physical exam, patients
IV site allergic reaction
1 (6.7)
1 (7)
were monitored by complete skin, oropharHeadache
1 (6.7)
1 (3)
yngeal, and nasal exams; for the second
A
Anemia was defined as a decrease in hemoglobin of >10% of the screening level. BReticulocytosis
cohort, patients were monitored by urinalysis
was defined as reticulocyte percentages of >2.6%. CAnemia of chronic disease (ACD) was defined
for hematuria at baseline and all subsequent
as subjects having both low iron and low total iron-binding capacity; at least one of these patients
D
study visits. A complete blood count with difhad superimposed iron deficiency (see Supplemental Figure 1). One episode of GI bleeding and
ferential and an extended metabolic panel,
the episode of polyarthralgia were categorized as severe adverse events, as each required hospital
including electrolytes and liver and renal funcadmission. EBoth subjects with epistaxis had prior history of epistaxis. FOne patient had prior history
of gingival bleeding. GOne event was witnessed by the Principal Investigator, while the other event
tion tests, were performed at each study visit.
was self-reported by patient.
Skin biomarker measurements. RNA was
collected from skin samples and placed
directly at the bedside into RNAlater. The
skin was minced and homogenized with a
Polytron homogenizer, RNA was purified using the RNeasy Mini Kit
were excluded. Patients were required to be on a stable dose of 10 mg
(Qiagen), and the concentration of total RNA was measured (Nanper day or less of prednisone and no other immunosuppressive medicaodrop 1000; ThermoScientific). 200 ng of RNA was used to make
tion. None of the patients received any immunosuppressive medications
cDNA, according to the SuperScript II RT (Invitrogen) protocol using
before the primary outcome measures, the biomarker skin biopsies,
random primers, and tested for THBS1, COMP, CTGF, SERPINE1, and
were performed at week 3 or 4 and week 7. Five patients were started
COL10A1 levels by RT-PCR, normalizing values to 18S RNA and then
on immunosuppressive therapy during the safety follow-up. GC02 was
normalizing the fold change to the average expression of RNAs from
started on methotrexate at week 11, which was discontinued, and the
5 healthy control skin samples. Primers were purchased from Applied
patient started on cyclophosphamide at week 17. GC03 was started on
Biosystems: THBS1 (Hs00962908_m1); COMP (Hs00164359_M1);
mycophenolate on week 15 after study withdrawal at the week 4 visit.
CTGF (Hs01026927_g1); SERPINE1 (Hs01126606_m1); and COL10A1
GC11 and GC12 were started on methotrexate at week 11. GC13 was
(Hs0016657_m1). RNA was also analyzed by microarray on Affymestarted on methotrexate on week 9.
trix U133A2.0 microarray chips, and data were normalized using the
Study design. Patients meeting inclusion criteria at the screenMAS 5.0 algorithm. Gene expression values were clustered using Clusing visit returned to the Boston University Medical Campus General
ter 2.0 (51). After filtering for genes showing differences of greater
Clinical Research Unit within 4 weeks. After an interim history and
than 200 across all samples, genes were mean centered, normalized,
physical examination, two 3-mm skin biopsies were performed on the
clustered by complete linkage, and visualized using Java Treeview.
dorsal surface of the mid-forearm: one biopsy was immediately placed
Further exploratory analyses for inflammatory genes were carried out
into 10% buffered formalin, and the other was placed into RNAlater
by clustering only genes selected on the basis of an expression cor(Qiagen). Study medication was then administered by intravenous
relating with the MRSS >0.4.
infusion. The first cohort, receiving 1 mg/kg fresolimumab, returned
RNA from skin biopsies was prepared and analyzed by microarafter 3 weeks for safety laboratory tests and repeat skin biopsies at sites
ray on Affymetrix U133A2.0 microarray chips. After filtering for genes
approximately 5 mm from but immediately adjacent to the initial biopshowing differences of greater than 200 across all samples, genes
sies, followed by a repeat 1 mg/kg dose of fresolimumab at week 4. Frewere mean centered, normalized, clustered by complete linkage using
solimumab was supplied by Genzyme under Investigational New Drug
Cluster 2.0 (51), and visualized using Java Treeview. All microarray
110704, granted to the Principal Study Investigator, Robert Lafyatis.
data have been deposited in the GEO database (accession GSE55036).
The second cohort, receiving a single dose of 5 mg/kg fresolimumab,
Immunohistochemical staining was carried out on formalinreturned at week 4 for safety laboratory tests and skin biopsies. Both
fixed, paraffin-embedded sections. For antigen retrieval, slides were
cohorts returned for follow-up safety monitoring at weeks 7, 11, 17, and

Table 4. Possible/probable drug-related adverse events in study patients
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incubated in citrate buffer pH 6.1 (Dako North America) for 20 minutes at 90°C. Sections were then incubated with a rabbit anti–PAI-1
(NBP2-13298, Novus Biologicals; 1:25 dilution) or mouse anti-SMA
(clone 1A4, M0851, Dako; 1:400 dilution). After washing, the sections were incubated with polymer/HRP solution (K5361, Dako) and
developed using DAB. Staining intensity was assessed by an observer
blinded to the patient and visit, as described previously (26). Collagen
thickness on trichrome-stained slides was measured using a Nikon
Eclipse E400 microscope and SPOT Software Advanced version 4.5.
Measurements were taken on each biopsy from the dermal epidermal
junction to the point at which collagen staining disappeared.
Statistics. Summary statistics, including the mean, median, standard deviation, and 95% confidence limits, are reported overall and
by dosing group for THBS1, COMP, and MRSSs at each time point and
for change from baseline to each follow-up time point. The Wilcoxon
signed-rank test was used to assess statistically significant changes
in each outcome for all available data for both dosing groups, combined and separately, and graphed using Prism software (GraphPad).
Spearman’s correlations were calculated to examine the relationships
between gene expression and MRSS.
For each outcome, a general linear model for correlated data was
used to incorporate all of the data into a single model and account for
potential correlation between repeated measurements on an individual. This approach uses all available data and is robust to “missingat-random” data mechanisms. An unstructured covariance was used
for all analyses. Each model contained terms for dosing group, categorical time, and their interaction. The interaction was removed to assess
the main effect of time. β Coefficients and corresponding standard
errors are reported. These analyses were performed using SAS v9.3.
The difference in immunohistochemical staining intensities and
autoantibody titers, comparing baseline and after treatment in each
patient, were analyzed using Wilcoxon signed-rank test. Statistical differences in the changes in skin score in patient groups showing different autoantibody status were compared using the Mann-Whitney test.
For predictive biomarker identification, Pearson correlations
between expression of each gene analyzed by microarray and the
difference in THBS1 expression at week 3 or 4 and week 7 compared
1. Roberts AB, Anzano MA, Wakefield LM, Roche NS,
Stern DF, Sporn MB. Type β transforming growth
factor: a bifunctional regulator of cellular growth.
Proc Natl Acad Sci U S A. 1985;82(1):119–123.
2. Roberts AB, et al. Transforming growth factor
type β: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen
formation in vitro. Proc Natl Acad Sci U S A.
1986;83(12):4167–4171.
3. Roberts AB, Heine UI, Flanders KC, Sporn MB.
Transforming growth factor-β. Major role in regulation of extracellular matrix. Ann N Y Acad Sci.
1990;580:225–232.
4. Penttinen RP, Kobayashi S, Bornstein P. Transforming growth factor β increases mRNA for
matrix proteins both in the presence and in the
absence of changes in mRNA stability. Proc Natl
Acad Sci U S A. 1988;85(4):1105–1108.
5. Derynck R, Miyaono K, eds. The TGF-Beta Family. Cold Spring Harbor Monograph Series 50.
Cold Spring Harbor, New York, USA: Cold Spring
Harbor Laboratory Press; 2007.
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with baseline were calculated. Changes in expression from baseline to week 3 or 4 and week 7 were treated as independent values
for these analyses. Genes showing correlations with fresolimumabassociated change in THBS1 expression of r < –0.4 or r < –0.6 were
selected for clustering. Using Cluster 2.0, genes were mean centered,
normalized, clustered by complete linkage, and visualized using Java
Treeview. Fisher’s exact test was used to calculate statistical significance on a contingency table, based on patients having higher or lower
than median baseline ADAM12 expression and having increased or
decreased THBS1 gene expression from baseline.
Study approval. The study was reviewed and approved by the Boston University Medical Campus Institutional Review Board, Boston,
Massachusetts, USA. All subjects provided informed consent prior to
their participation in the study.
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